GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR technology and structure-based drug design platform... Dec 22
Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease... Dec 16
-Advertisements-